Alkermes to Present Data on Aripiprazole Lauroxil and ALKS 3831 at 15th International Congress on Schizophrenia Research
March 23 2015 - 7:00AM
Business Wire
Alkermes plc (NASDAQ: ALKS) today announced that clinical data
on aripiprazole lauroxil, an investigational, novel, long-acting
injectable atypical antipsychotic for the treatment of
schizophrenia, and ALKS 3831, an investigational, novel, oral
atypical antipsychotic drug candidate designed to be a
broad-spectrum treatment for schizophrenia, are scheduled to be
presented at the 15th International Congress on Schizophrenia
Research (ICOSR) in Colorado Springs, Colo., March 28-April 1,
2015.
Key poster presentations include:
Sunday, March 29, 2015, 12:00 – 2:00 p.m.
MDT
Poster 90: “Effects of Aripiprazole Lauroxil on Agitation and
Hostility in Patients with Schizophrenia” will be presented by
Leslie Citrome, M.D., MPH, Clinical Professor of Psychiatry and
Behavioral Sciences at New York Medical College.
Poster 142: “A Phase 2, Randomized, Olanzapine-Controlled Study
of the Safety, Tolerability and Efficacy of ALKS 3831 in Adults
with Schizophrenia” will be presented by Bernard Silverman, M.D.,
Vice President, Clinical Science and Drug Safety, Alkermes,
Inc.
Poster 145: “Effect of Aripiprazole Lauroxil on Metabolic and
Endocrine Profiles, and Related Safety Considerations in Acute
Schizophrenia” will be presented by Henry Nasrallah, M.D.,
Chair, Department of Neurology and Psychiatry at Saint
Louis University School of Medicine.
Poster 146: “Efficacy and Safety of Aripiprazole Lauroxil in
Patients Experiencing Severe Psychotic Symptoms During an Acute
Exacerbation of Schizophrenia” will be presented by Steven Potkin,
M.D., Director of Clinical Research and Professor of Psychiatry,
Psychiatry & Human Behavior at the University of California
Irvine School of Medicine.
Poster 147: “Effect of Aripiprazole Lauroxil on Personal and
Social Functioning and Health-Related Quality of Life Among
Patients with Schizophrenia” will be presented by Peter Weiden,
M.D., Professor of Psychiatry at the University of Illinois Medical
Center.
A full list of all Alkermes posters being presented at the ICOSR
meeting is available at http://www.schizophreniacongress.org/.
About Aripiprazole
Lauroxil
Aripiprazole lauroxil is an injectable atypical antipsychotic
with one-month and extended-duration formulations in development
for the treatment of schizophrenia. Once in the body, aripiprazole
lauroxil converts to aripiprazole, which is commercially available
under the name ABILIFY®. As a long-acting investigational
medication based on Alkermes’ proprietary LinkeRx® technology,
aripiprazole lauroxil is designed to have multiple dosing options
and to be administered in a ready-to-use, pre-filled product
format.
About ALKS 3831
ALKS 3831 is a proprietary, investigational medicine designed as
a broad-spectrum antipsychotic for the treatment of schizophrenia.
ALKS 3831 is composed of samidorphan, a novel, potent mu-opioid
antagonist, in combination with the established antipsychotic drug,
olanzapine. ALKS 3831 is designed to attenuate olanzapine-induced
metabolic side effects, including weight gain, in patients with
schizophrenia and to have utility in the treatment of schizophrenia
in patients with alcohol use.
About Alkermes
Alkermes plc is a fully integrated, global
biopharmaceutical company developing innovative medicines for the
treatment of central nervous system (CNS) diseases. The company has
a diversified commercial product portfolio and a substantial
clinical pipeline of product candidates for chronic diseases that
include schizophrenia, depression, addiction and multiple
sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an
R&D center in Waltham, Massachusetts; a research and
manufacturing facility in Athlone, Ireland; and manufacturing
facilities in Gainesville, Georgia and Wilmington, Ohio. For more
information, please visit Alkermes’ website
at www.alkermes.com.
Note Regarding Forward-Looking
Statements
Certain statements set forth in this press release constitute
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, as amended, including,
but not limited to, statements concerning the therapeutic value of
aripiprazole lauroxil and ALKS 3831. You are cautioned that
forward-looking statements are inherently uncertain. Although the
company believes that such statements are based on reasonable
assumptions within the bounds of its knowledge of its business and
operations, the forward-looking statements are neither promises nor
guarantees and are subject to a variety of risks and uncertainties,
many of which are beyond the company’s control, which could cause
actual results to differ materially from those expressed or implied
in the forward-looking statements. These risks and uncertainties
include, among others, whether preclinical and clinical results for
ALKS 3831 will be predictive of future clinical study results;
whether ALKS 3831 or aripiprazole lauroxil could be shown to be
unsafe or ineffective; and those risks described in the Alkermes
plc Annual Report on Form 10-K for the fiscal year ended Dec. 31,
2014, and in any other subsequent filings made by the company with
the U.S. Securities and Exchange Commission (SEC), which are
available on the SEC’s website at www.sec.gov. The information
contained in this press release is provided by the company as of
the date hereof, and, except as required by law, the company
disclaims any intention or responsibility for updating or revising
any forward-looking information contained in this press
release.
LinkeRx® is a registered trademark of Alkermes Pharma Ireland
Limited Corporation. ABILIFY® is a registered trademark of Otsuka
Pharmaceutical Co., Ltd.
Alkermes Contacts:For
Investors:Rebecca Peterson, +1 781-609-6378orFor Media:Jennifer
Snyder, +1 781-609-6166
Alkermes (NASDAQ:ALKS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alkermes (NASDAQ:ALKS)
Historical Stock Chart
From Apr 2023 to Apr 2024